As per reports, Kenvue, Johnson & Johnson’s (JNJ) newly formed consumer health unit files on the New York Stock Exchange to be listed as an independent company, more than a year after the consumer giant announced its plan to break up into two companies. The filing, for Kenvue will be listed under the ticker symbol “KVUE”. The consumer unit has also faced nearly 40,000 lawsuits alleging that its baby powder/ talc products contained asbestos that caused mesothelioma and ovarian cancer in women who used it for personal hygiene, however, the company has denied the claims.
Recently, Rival GlaxoSmithKline completed the spin-off of its consumer health business. J&J will continue to hold at least 80.1% of the voting power of Kenvue’s shares upon completion of the offering.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
Consider visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury.
READ THIS PROGRESS REPORT TOO…
On January 10, InMed Pharmaceuticals Inc. (Nasdaq: INM) issued a press release, which outlined their key accomplishments from 2022 and provided business update and catalysts for 2023 including the following interesting milestones for 2023:
- Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023
- Progress preclinical research in glaucoma in preparation for human trials
- Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
REVIEWING InMed’s 2022 ACCOMPLISHMENTS
INM-755 in Epidermolysis Bullosa
Activated 11 clinical trial sites in seven countries for the Phase 2 study
Expanded from adult subjects to include adolescents following independent review of early safety data
Progressed clinical trial with enrollment and treatment of 15 patients, with the 16th patient enrolled for treatment in early January 2023